These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy. Valdecantos MP; Ruiz L; Pardo V; Castro-Sanchez L; García-Monzón C; Lanzón B; Rupérez J; Barbas C; Naylor J; Trevaskis JL; Grimsby J; Rondinone CM; Valverde ÁM Sci Rep; 2018 Nov; 8(1):16461. PubMed ID: 30405191 [TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139 [TBL] [Abstract][Full Text] [Related]
4. Mosapride citrate improves nonalcoholic steatohepatitis with increased fecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a rodent model. Okubo H; Nakatsu Y; Sakoda H; Kushiyama A; Fujishiro M; Fukushima T; Matsunaga Y; Ohno H; Yoneda M; Kamata H; Shinjo T; Iwashita M; Nishimura F; Asano T Am J Physiol Gastrointest Liver Physiol; 2015 Jan; 308(2):G151-8. PubMed ID: 25428903 [TBL] [Abstract][Full Text] [Related]
5. Metabolic impact of partial hepatectomy in the non-alcoholic steatohepatitis animal model of methionine-choline deficient diet. Carril E; Valdecantos MP; Lanzón B; Angulo S; Valverde ÁM; Godzien J; Rupérez FJ J Pharm Biomed Anal; 2020 Jan; 178():112958. PubMed ID: 31718984 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients. Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435 [TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915 [TBL] [Abstract][Full Text] [Related]
8. Cangju Qinggan Jiangzhi Decoction Reduces the Development of NonAlcoholic Steatohepatitis and Activation of Kupffer Cells. Cheng Y; Chen T; Ping J; Chen J Cell Physiol Biochem; 2018; 48(3):971-982. PubMed ID: 30036865 [TBL] [Abstract][Full Text] [Related]
10. Diallyl disulfide attenuates non‑alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, lipid peroxidation and inflammation in mice. Zhang N; Wang Y; Zhang J; Liu B; Li G; Xin S; Xu K Mol Med Rep; 2019 Aug; 20(2):1363-1372. PubMed ID: 31173200 [TBL] [Abstract][Full Text] [Related]
11. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation. Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620 [TBL] [Abstract][Full Text] [Related]
13. Theabrownin ameliorates liver inflammation, oxidative stress, and fibrosis in MCD diet-fed C57BL/6J mice. Zhen Q; Liang Q; Wang H; Zheng Y; Lu Z; Bian C; Zhao X; Guo X Front Endocrinol (Lausanne); 2023; 14():1118925. PubMed ID: 36742397 [TBL] [Abstract][Full Text] [Related]
14. Treatment with geraniol ameliorates methionine-choline-deficient diet-induced non-alcoholic steatohepatitis in rats. Chen J; Fan X; Zhou L; Gao X J Gastroenterol Hepatol; 2016 Jul; 31(7):1357-65. PubMed ID: 26695085 [TBL] [Abstract][Full Text] [Related]
15. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Ding Y; Sun X; Chen Y; Deng Y; Qian K Eur J Pharmacol; 2015 Aug; 761():405-12. PubMed ID: 25967348 [TBL] [Abstract][Full Text] [Related]
16. Hepatoprotective and antioxidant activities of extracts from Salvia-Nelumbinis naturalis against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet in mice. Liu Y; Song H; Wang L; Xu H; Shu X; Zhang L; Li Y; Li D; Ji G J Transl Med; 2014 Nov; 12():315. PubMed ID: 25406833 [TBL] [Abstract][Full Text] [Related]
17. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284 [TBL] [Abstract][Full Text] [Related]
18. Protective role of autophagy in methionine-choline deficient diet-induced advanced nonalcoholic steatohepatitis in mice. Chen R; Wang Q; Song S; Liu F; He B; Gao X Eur J Pharmacol; 2016 Jan; 770():126-33. PubMed ID: 26593434 [TBL] [Abstract][Full Text] [Related]
19. Dynamics of oxidative/nitrosative stress in mice with methionine-choline-deficient diet-induced nonalcoholic fatty liver disease. Jorgačević B; Mladenović D; Ninković M; Prokić V; Stanković MN; Aleksić V; Cerović I; Vukićević RJ; Vučević D; Stanković M; Radosavljević T Hum Exp Toxicol; 2014 Jul; 33(7):701-9. PubMed ID: 24130212 [TBL] [Abstract][Full Text] [Related]
20. Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice. Kammoun HL; Allen TL; Henstridge DC; Kraakman MJ; Peijs L; Rose-John S; Febbraio MA PLoS One; 2017; 12(6):e0179099. PubMed ID: 28632778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]